ErlySign Gets CDSCO Nod for Trials for Oral Cancer Detection Technology

ErlySign Gets CDSCO Nod for Trials for Oral Cancer Detection Technology

By, Admin 9 April 2024

ErlySign gets CDSCO nod for large-scale clinical trials for oral cancer detection technology

Overview

ErlySign, a Nagpur-based biotech start-up received the approval from the Central Drugs Standard Control Organization (CDSCO) for its active salivary biomarker study designed for early cancer detection.

Approval for Large-Scale Trial

  • Following a comprehensive year-long investigation and based on in-house validation data of 150 test samples, the Indian Regulatory Authority CDSCO has granted permission to ErlySign to proceed with large-scale clinical trials. 
  • Notably, during the initial studies, ErlySign's active salivary biomarker study showcased remarkable performance, demonstrating a sensitivity of 98% and an unparalleled specificity of 100%. 

Revolutionizing Technology

  • The proprietary technology developed by ErlySign promises to revolutionise cancer detection through its advanced approach. 
  • The company has also launched an automated multi-sample reader for its oral cancer detection kit. 
  • This streamlines the testing process, allowing multiple tests to be processed within a mere 15-20 minutes. 

Words from CEO: ErlySign

"Our mission is to provide an easy, accurate, affordable, and painless solution for early cancer detection. The active salivary biomarker study, now approved by CDSCO, marks a significant step towards achieving this goal. With our technology, individuals can now detect precancerous conditions even before the appearance of any oral lesion or tumour formation, empowering proactive intervention and potentially saving countless lives,” stated Shubhendra Singh Thakur, CEO, ErlySign.

Oral Cancer Detection Kit

  • The company said that its oral cancer detection kit offers a semi-quantitative approach, allowing for the assessment of pre-cancerous conditions through saliva biomarkers. 
  • Results are provided as low, moderate, or high risk, providing individuals with actionable insights into their cancer risk profile.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!